Contribution: Industrial Research Assistance Program – Contributions to Firms
Providence Therapeutics Holdings Inc.
$8,660,000.00
Providence COVID-19 Vaccine Development - Stage 2
FY 2021-22 · 2021-07-23
Summary
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Calgary|Calgary, Alberta, Canada
Recipient Type
For-profit organization
Business Number
738045079
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-07-23 | 2021-22 | $8,600,000.00 |
| 1 | 2021-07-23 | 2021-22 | $8,660,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 60,000 dollars. Calgary Midnapore 48008
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 60 000 dollars. Calgary Midnapore 48008
Agreement End Date
2022-11-30
Agreement Number
976618
Agreement Start Date
2021-07-23
Agreement Title
Providence COVID-19 Vaccine Development - Stage 2
Agreement Title (French)
Développement du vaccin Providence COVID-19 - Phase 2
Agreement Type
Contribution
Agreement Value
$8,660,000.00
Amendment Date
2022-03-30
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Description (French)
L'entreprise est le chef de file canadien dans le domaine des ARNm thérapeutiques et le principal objectif de ce projet est de poursuivre le développement du PTX-COVID19-B en menant un essai clinique de phase II. Le but est de commercialiser un vaccin à ARNm COVID-19 fabriqué au Canada et de développer et valider des vaccins à ARNm ciblant les variants préoccupants de la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Calgary Shepard
Federal Riding (French)
Calgary Shepard
Federal Riding Number
48011
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
738045079
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
Providence Therapeutics Holdings Inc.
Recipient Postal Code
T2Z 3P2
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2021-2022-Q2-976618
